carbamates has been researched along with Dyskinesia, Medication-Induced in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although levodopa improves PD symptoms in the initial stages of the disease, its long-term use is limited by the development of side effects, including abnormal involuntary movements (dyskinesias) and psychiatric complications." | 1.34 | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. ( Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG, 2007) |
| "= 2." | 1.29 | D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. ( Bartsch, R; Engel, J; Hönack, D; Kutscher, B; Löscher, W; Polymeropoulos, EE; Rostock, A; Rundfeldt, C; Tober, C; White, HS; Wolf, HH, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnston, TH | 1 |
| Huot, P | 1 |
| Fox, SH | 1 |
| Wakefield, JD | 1 |
| Sykes, KA | 1 |
| Bartolini, WP | 1 |
| Milne, GT | 1 |
| Pearson, JP | 1 |
| Brotchie, JM | 1 |
| Sander, SE | 1 |
| Lemm, C | 1 |
| Lange, N | 1 |
| Hamann, M | 1 |
| Richter, A | 1 |
| Morgese, MG | 1 |
| Cassano, T | 1 |
| Cuomo, V | 1 |
| Giuffrida, A | 1 |
| Rostock, A | 1 |
| Tober, C | 1 |
| Rundfeldt, C | 1 |
| Bartsch, R | 1 |
| Engel, J | 1 |
| Polymeropoulos, EE | 1 |
| Kutscher, B | 1 |
| Löscher, W | 1 |
| Hönack, D | 1 |
| White, HS | 1 |
| Wolf, HH | 1 |
| Heinze, M | 1 |
| Andreae, D | 1 |
| Grohmann, R | 1 |
| Leinot, M | 1 |
| Benoit, J | 1 |
| Basiez, M | 1 |
| Meunier, A | 1 |
| Labrid, C | 1 |
6 other studies available for carbamates and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Callithrix; Carbamates; Disease Models, Animal; Dyskin | 2011 |
Retigabine, a K(V)7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Amantadine; Aminopyridines; Animals; Anticonvulsants; Antiparkinson Agents; Behavior, Animal; Carbam | 2012 |
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzox | 2007 |
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.
Topics: Administration, Oral; Animals; Anticonvulsants; Behavior, Animal; Bicuculline; Carbamates; Dyskinesi | 1996 |
Rivastigmin and impaired motor function.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Catatonia; Dyskinesia, Drug-Induced; Female; | 2002 |
[Comparaison, in the mouse, of two treatments for alcohol withdrawal syndrome. Inhibition of oxo tremorine-induced tremor, sedative and motor effects (author's transl)].
Topics: Alcoholism; Animals; Antipsychotic Agents; Barbiturates; Benzamides; Carbamates; Dyskinesia, Drug-In | 1979 |